About

Mark Parry has worked with Intertek for over 20 years since graduating from Cambridge University (UK) and currently works as the Senior Scientific Director, supporting the wide range of analytical, formulation, product development and research activities across the company. Mr Parry has worked in a range of pharmaceutical analysis and formulation development areas, with a particular focus on inhaled and nasal drug products. Mostly working in the pre-approval stages, Mr Parry’s background includes extensive experience with product and formulation development, as well as method development and validation, stability studies and pharmaceutical development activities for a wide range of clients across the pharmaceutical industry.

Contributions

EXPERT VIEW

CONSIDERATIONS WHEN SWITCHING FROM CURRENT pMDI PROPELLANTS TO NEW LOWER-GWP PROPELLANTS

Mark Parry discusses the considerations that need to be made when switching from current pressurised metered dose inhaler propellants to new alternatives with lower global warming potential, including formulation, regulatory and analytical standpoints.

More contributions

PULMONARY

IN VITRO BIOEQUIVALENCE – WHERE ARE WE NOW?

With a focus on bioequivalence testing in generic inhalables development, Mark Parry highlights shortcomings of aerodynamic particle size distribution and delivered dose testing, and introduces newer testing techniques.